Truist Securities Maintains Buy on Revolution Medicines, Raises Price Target to $241
Benzinga Newsdesk 2 weeks ago
Analyst RatingsNewsPrice Target
Truist Securities analyst Gregory Renza maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price target from $240 to $241.
Truist Securities analyst Gregory Renza maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price target from $240 to $241.